Curaxys SL. is the unique Spanish biotechnology company that researches, develops, produces and commercializes biosimilars in a single integrated process for combating diseases of high incidence in society as breast cancer.
Curaxys hires five more technologists with the support of the Inncorpora Program granted by the Ministry of Economy and Competitiveness.
Curaxys S.L. and Obras Coman S.A. have signed a contract to excecute a Biopharma Plant to produce biological medicines and other recombinant proteins to cure different diseases like cancer.
Innovaxis, first Enterprise that commercializes advances therapies and tissue regeneration integrating HTS services.
A Technological and Commercial Strategic Alliance leading I+D of generic and biogeneric compounds for cancer disease.
Curaxys CEO will dedicate their practice in biological drug development and will train researchers and biotechnology managers
More on Curaxys
The Andalusian pharmaceutical company, Curaxys, is ranked among the world top ten companies.
|We focus on the research, production and commercialization of recombinant proteins added value through the utilization of CuraMab® with specific human cell lines
|Our expression system allows us to reach of recombinant protein levels that are clearly above those currently available.
|We developed a downstream technological platform on the basis of our own laboratory data.